ReNeuron Group plc

("ReNeuron" or the "Company")

New Senior Appointment Strengthening Exosomes Expertise  

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.

Dr Randolph Corteling has 24 years' experience in medical research and drug discovery, spanning academia, biotechnology and the pharmaceutical industry. He gained his PhD in Medical and Surgical Sciences at Nottingham University, followed by three years as a Heart and Stroke Foundation Postdoctoral Fellow at the University of Calgary, Canada.

In 2007 he joined ReNeuron as a senior member of the research team where he established a deep understanding of stem cell biology and in particular the role of extracellular vesicles in cell-to-cell communication. In 2011 he was appointed Head of Cell Biology where he established the first exosome programmes at ReNeuron, which are now a major commercial opportunity for the Company. He was later promoted to Head of Research at ReNeuron.

Since 2020, Dr Corteling has worked at Evox Therapeutics, a private company focused on Exosome based therapeutics for rare diseases, where he led their Disease Biology and Exosome Payloads teams.

Olav Hellebø, Chief Executive Officer, commented: "We are delighted to welcome Randolph back to ReNeuron. His knowledge and experience in the field of therapeutic exosomes and partnered programmes will be invaluable to us as we seek to continue to build and expand our exosome platform."

                                                                                                                ENDS

Contacts:

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell and Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for disease with significant unmet needs.

The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa. The Company has also out-licensed its CTX programme in stroke disability to Fosun in China.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com